Last updated: August 8, 2025
Introduction
Japan Patent JP2021191756, filed in 2021, relates to innovative developments in the pharmaceutical sector, with implications across drug composition, formulation, and delivery mechanisms. This analysis dissects the patent's scope and claims, positioning it within Japan’s broader pharmaceutical patent landscape, and evaluates strategic considerations for stakeholders.
Scope and Core Claims
Patent Summary
JP2021191756 concerns a novel pharmaceutical composition aimed at enhancing therapeutic efficacy while reducing adverse effects. It focuses on a specific drug delivery system, comprising a novel excipient or carrier that modulates bioavailability or targeted delivery.
Claims Dissection
The patent’s claims can be broadly categorized into:
-
Claim 1: An isolated pharmaceutical composition comprising an active ingredient and a unique carrier system that controls release characteristics, wherein the carrier is characterized by specific polymeric properties.
-
Claim 2: The composition of claim 1, wherein the active ingredient is an anti-inflammatory agent, such as a corticosteroid or NSAID, specifying a particular molecule or class.
-
Claim 3: The composition wherein the carrier is a biodegradable polymer that degrades at a predetermined rate, facilitating sustained drug release.
-
Claim 4: A method of manufacturing the composition described in claim 1, involving specific processing steps, such as emulsification or encapsulation methods.
-
Claim 5: The pharmaceutical formulation for oral, injectable, or transdermal administration, emphasizing the versatility of delivery.
Scope of Protection
The claims extend protection primarily to:
- Drug compositions featuring the specific carrier system detailed.
- Use of the composition for treating inflammatory conditions.
- Manufacturing processes using the described carrier.
This scope effectively covers both the formulation itself and potential therapeutic applications, providing broad territorial and functional protection, especially in the context of sustained-release systems.
Patent Landscape Context
Existing Patents and Similar Technologies
Japan’s pharmaceutical patent landscape has historically included:
- Patents on novel polymers serving as drug carriers, notably biodegradable and bioresorbable polymers.
- Formulation patents for controlled-release compositions, especially for NSAIDs and corticosteroids.
- Delivery system innovations, including microencapsulation and nanoparticle-based carriers.
JP2021191756 appears to build upon these prior art bases, incorporating specific polymeric properties and manufacturing methods to differentiate from existing patents.
Key Competitors and Patent Players
Major players within Japan’s pharmaceutical innovation space, such as Daiichi Sankyo, Takeda, and Astellas, hold patents on advanced drug delivery systems. International firms like Pfizer and Merck also maintain extensive patent portfolios.
JP2021191756's detailed focus on polymer selection and manufacturing processes can serve as a strategic defensive patent, as well as an enabler for licensee partnerships.
Potential Overlaps and Novelty
While the use of biodegradable polymers and controlled-release formulations are standard in drug delivery patents, the specific combination of polymer properties, degradation rate, and manufacturing process claimed herein may confer novelty and inventive step, assuming prior art does not disclose this exact configuration.
In the Japanese market, a thorough search of prior patents, including those in the Japanese Patent Gazette and PCT applications, would be necessary to evaluate definitiveness fully and assess the scope of patentability.
Legal and Strategic Considerations
-
Patentability: The claims likely rely on the unique polymer properties and manufacturing steps. Demonstrating inventive step will hinge on the specific polymer chemistry and processing innovations.
-
Enforceability: The breadth of claims supports enforcement against infringing formulations that employ similar carrier systems, especially in targeted therapeutic areas such as inflammation.
-
Lifecycle: The patent's term expires in 2041–2042, offering adequate market exclusivity for product development, pending maintenance fees and potential disputes.
-
Freedom-to-Operate (FTO): Companies should conduct detailed freedom-to-operate analyses to ensure the novel polymer composition does not infringe upon existing patents, especially given Japan's dense patent landscape in drug delivery systems.
Implications for R&D and Market Strategy
This patent enhances competitive positioning for firms developing sustained-release formulations, particularly in inflammatory diseases. Strategic licensing could facilitate access to proprietary polymer technology and manufacturing processes, while also serving as a defensive patent in the crowded Japan pharmaceutical market.
Key Takeaways
- The scope covers innovative controlled-release compositions with specific polymer characteristics, applicable across multiple administration routes.
- Strong strategic positioning arises from the broad utility and detailed claims that protect both the formulation and manufacturing process.
- Companies should perform a comprehensive patent landscape analysis to identify potential overlaps and opportunities, especially considering existing polymer-based delivery patents.
- Collaborations and licensing avenues may accelerate commercialization, leverage proprietary technology, and mitigate infringement risks.
- Maintaining patent lifecycle management and monitoring competitor filings are critical to sustaining market exclusivity and innovation leadership.
Conclusion
JP2021191756 positioning aligns well with Japan's emphasis on advanced drug delivery systems. Its detailed claims, covering composition, manufacturing, and therapeutic use, provide a substantial strategic IP asset. Thorough landscape analysis and vigilant patent monitoring will be essential for effective commercialization and competitive advantage.
FAQs
Q1: How does JP2021191756 compare with existing controlled-release patents in Japan?
A1: Its focus on specific biodegradable polymers and manufacturing methods distinguishes it by potentially offering novel combinations not previously disclosed, which may confer patentability and competitive edge.
Q2: What therapeutic areas benefit most from this patent’s innovations?
A2: Primarily inflammatory diseases, including arthritis or asthma, where sustained-release formulations of corticosteroids or NSAIDs are beneficial.
Q3: Can this patent be extended to international markets?
A3: Yes, through filing corresponding patents via PCT or direct applications in other jurisdictions, provided similar novelty and inventive step assessments are satisfied.
Q4: What are common risks associated with patent infringement in Japan’s pharmaceutical landscape?
A4: Overlapping claims, prior art disclosures, and broad claim scopes can pose infringement risks; thus, thorough patent landscape analysis is crucial.
Q5: How essential is manufacturing process innovation in strengthening patent protection?
A5: Very; detailed manufacturing processes can serve as independent claims or provide robustness to composition claims, reducing workaround possibilities.
References
[1] Japan Patent Office public records and patent databases.
[2] Recent PCT applications related to polymer-based drug delivery systems.
[3] Industry reports on controlled-release formulations in Japan.
